Paediatric basis of adult lung disease

Louis I Landau1

  • 1School of Paediatrics and Child Health, The University of Western Australia, Australia. llandau@cyllene.uwa.edu.au

Insights

Early life factors and genetics significantly influence lifelong lung disease development. Understanding these programming mechanisms is crucial for developing new treatments for conditions like asthma and cystic fibrosis.

Area of Science:

  • Pulmonology
  • Developmental Biology
  • Immunology

Background:

  • Lung disease is often programmed during fetal development and early infancy.
  • Maternal factors like smoking and diet, alongside genetic predispositions (e.g., cystic fibrosis, asthma), impact lung health.
  • Early life exposures to pathogens, allergens, and helminths influence the development of asthma and allergies.

Purpose of the Study:

  • To explore the early programming mechanisms that dictate lifelong lung health and disease.
  • To highlight the interplay between genetic predisposition and environmental factors in early lung development.
  • To inform the development of novel therapeutic strategies targeting early life interventions.

Main Methods:

  • Review of existing literature on fetal and early postnatal lung development.
  • Analysis of genetic and environmental factors contributing to lung disease.
  • Examination of the timing of exposures in relation to disease outcomes.

Main Results:

  • Prenatal and early postnatal environments critically shape lung function and immunity.
  • Genetic factors are key determinants for specific lung diseases like cystic fibrosis and asthma.
  • The timing of exposure to various agents in early life impacts the trajectory of allergic and asthmatic conditions.

Conclusions:

  • Lung disease programming begins in utero and early infancy, influenced by genetics and environment.
  • Abnormal airway structure is observed in wheezing disorders, linked to early developmental processes.
  • Future therapeutic and environmental interventions must consider these early programming mechanisms for effective lung disease management.

Related Concept Videos

Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...